Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6.

View in: PubMed

subject areas

Aged
Angiogenesis Inhibitors
Antineoplastic Agents
Carcinoma, Transitional Cell
Combined Modality Therapy
Disease-Free Survival
Fatigue
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins
Salvage Therapy
Treatment Failure
Urologic Neoplasms
Vascular Endothelial Growth Factor A

authors with profiles

Walter M. Stadler